New drug therapy could improve brain function and life expectancy of ALS patients

(American Associates, Ben-Gurion University of the Negev) The Ben-Gurion U. researcher successfully redesigned a portion of MabThera, an FDA-approved drug used to treat certain autoimmune diseases and types of cancer, into a new molecule to treat ALS. 'Our experimental results on ALS transgenic mice showed a significant increase in life expectancy,' says Dr. Lichtenstein. 'Since the drug is already approved, we believe that we will only need limited preclinical testing to reach the clinical phase earlier than other initiatives.'

https://www.eurekalert.org/pub_releases/2017-05/aabu-ndt052317.php

Source: EurekAlert! - Cancer - May 25, 2017 Category: Cancer & Oncology Source Type: news